Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China.

ABSTRACT:

Background

HER2 mutation is found in 1%-2% of lung cancer patients. Studies comparing chemotherapy to HER2-TKIs are limited. This study aimed to investigate the molecular and clinical patterns of HER2 mutations in advanced non-small cell lung cancer (NSCLC), and compare the different outcomes between chemotherapy and HER2-TKIs.

Methods

Advanced or recurrent non-small cell lung cancer patients with de novo HER2 mutations (N = 75) were included in this study. Molecular information, clinical features, and treatment outcomes were retrospectively collected from a web-based patient registry and hospital chart review.

Results

Between October 2012 and December 2018, 65 patients with in-frame insertion mutations, eight with point mutations and two with gene amplification were

SUBMITTER: Xu F 

PROVIDER: S-EPMC7049517 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature